Q2 EPS Estimates for IceCure Medical Increased by Analyst

IceCure Medical Ltd. (NASDAQ:ICCM) – Stock analysts at Brookline Capital Markets lifted their Q2 2026 earnings per share (EPS) estimates for shares of IceCure Medical in a research note issued to investors on Monday, June 22nd. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will earn ($0.95) per share for the quarter, up from their prior estimate of ($1.80). The consensus estimate for IceCure Medical’s current full-year earnings is ($4.50) per share. Brookline Capital Markets also issued estimates for IceCure Medical’s Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($3.51) EPS, FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($1.26) EPS, FY2029 earnings at $0.88 EPS and FY2030 earnings at $3.21 EPS.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.03). The business had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%.

Several other research analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Maxim Group reduced their price target on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Finally, Alliance Global Partners started coverage on shares of IceCure Medical in a research note on Monday, May 4th. They issued a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, IceCure Medical has an average rating of “Hold” and an average price target of $62.70.

IceCure Medical Stock Up 52.0%

Shares of IceCure Medical stock opened at $9.30 on Thursday. IceCure Medical has a 52 week low of $2.12 and a 52 week high of $42.00. The firm’s 50 day moving average is $6.85 and its two-hundred day moving average is $13.93. The firm has a market capitalization of $26.13 million, a P/E ratio of -1.29 and a beta of 0.40.

Hedge Funds Weigh In On IceCure Medical

A number of hedge funds have recently modified their holdings of ICCM. Virtu Financial LLC acquired a new position in shares of IceCure Medical in the 4th quarter valued at $39,000. Jane Street Group LLC acquired a new stake in IceCure Medical during the 4th quarter worth $67,000. Finally, Concurrent Investment Advisors LLC purchased a new position in IceCure Medical during the 4th quarter worth $48,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.